Started with congestive heart failure research
Vesely began his research on cardiac hormones by looking at the role they can play in diagnosing and treating congestive heart failure. Following his wifes death from breast cancer in 2002 -- and as it became clear that the hormones controlled cell growth -- he decided to place the hormones into cancer cell cultures.
Using colon, ovarian, breast, prostate and pancreatic cancer cells, among others, Vesely found that the hormones kill up to 97% of all cancers in cell cultures within 24 hours. He then turned to trials with mice, injecting some with pancreatic cancer cells and others with breast cancer cells. Once the mice developed tumors, he treated them with the hormones.
At the end of one month, the treatment had eliminated cancer in 80% of the mice injected with human pancreatic cancer and in 66% of the mice injected with breast cancer. The results with pancreatic cancer were particularly exciting because it is a fast-moving cancer with poor prognosis.
No side effects in mice
The pancreatic cancers that were not cured were reduced to less than 10% of their original size. Treatment with vessel dilator gave the best results: reducing the tumor to 2% of its largest size. None of the mice died of cancer all died of old age and none suffered any side effects.
None of the mice received any other course of treatment such as surgery, chemotherapy or radiation and they did not suffer any side effects. After the mice died at the end of a normal life span, the researchers found that the cancer had not spread. If the hormones act the same way in humans, cancer could become a chronic condition treatable with these hormones, Vesely said.
A private biotechnology company is raising money to begin human trials, Vesely said. The Haley hospital and University of South Florida hold the patents on the discoveries.
The symposium that
'/>"/>
| Contact: Christine Guilfoy cguilfoy@the-aps.org 301-634-7253 American Physiological Society Source:Eurekalert |